Losing Sight with AMD
As we age, most people both expect and accept that they will not be able to do 100% of the things they could as young bucks. But sadly for many, loss of vision with age is an unwelcome and harsh reality. Age-related macular degeneration (AMD) is the most common cause of vision loss among aging adults and a frequent issue for people over 50. However, with new therapies and research, the tide could be turning for treating this disease. Fine Points According to the National Eye Institute ( NEI ), AMD causes loss of vision by slowly deteriorating the macula, a very sensitive part o...
Cancer Drug Reaffirmed for Macular Degeneration
A second trial has affirmed that cancer drug Avastin ( bevacizumab ) is an effective cost efficient treatment for patients suffering from age-related macular degeneration (AMD), which can lead to blindness.
IV Drugs Equal for Treating Macular Degeneration
Two medications commonly used to treat age-related macular degeneration (AMD) have been found to provide equal treatment benefit in the first long-term study comparing the drugs. Injectable drugs Avastin ( bevacizumab ), an off-label cancer medication most frequently used to treat AMD, and Lucentis ( ranibizumab ), approved to treat AMD by the U.S. Food and Drug Administration in 2006, both provided similar vision improvements at two years. Get regular vision exams to pinpoint vision loss early. Maureen Maguire, PhD, corresponding author and director of the Center for Preventi...
FDA Alerts: Avastin
The U.S. Food and Drug Administration (FDA) is alerting health care professionals that repackaged intravitreal injections of Avastin ( bevacizumab ) have caused a cluster of serious eye infections in the Miami, Florida area.